Bionano Announces Publication Reporting First Use of OGM to Detect Chromoanagenesis, a Key Marker of Poor Prognosis in AML

Core Insights - Bionano Genomics, Inc. announced a study demonstrating the utility of optical genome mapping (OGM) for detecting structural variants associated with chromoanagenesis (CAG) in acute myeloid leukemia (AML) [1][4] - The study found that CAG was present in 16% of AML cases, with approximately two-thirds of high-risk cytogenetic profiles showing this variant, indicating OGM's higher sensitivity compared to traditional methods [1][9] - The median survival for AML patients with CAG was significantly lower at 5 months compared to 14 months for those without CAG, highlighting the importance of early detection for treatment planning [9] Study Details - The study analyzed a cohort of 410 AML cases and was led by Dr. Guilin Tang from MD Anderson Cancer Center, marking the first known use of OGM to study CAG [2] - OGM demonstrated high resolution and sensitivity in detecting catastrophic chromosomal events, reinforcing its potential to refine AML risk stratification [9] Company Overview - Bionano Genomics provides genome analysis solutions aimed at transforming the understanding of the genome through OGM, diagnostic services, and software [5] - The company offers OGM solutions for various research applications and has developed a platform-agnostic genome analysis software solution [5]